ProQR Therapeutics N.V. (PRQR)
 NASDAQ: PRQR · Real-Time Price · USD
 2.720
 +0.070 (2.64%)
  At close: Oct 30, 2025, 4:00 PM EDT
2.700
 -0.020 (-0.74%)
  After-hours: Oct 30, 2025, 7:02 PM EDT
ProQR Therapeutics Revenue
ProQR Therapeutics had revenue of 3.98M EUR in the quarter ending June 30, 2025, a decrease of -38.48%. This brings the company's revenue in the last twelve months to 17.14M, up 8.65% year-over-year. In the year 2024, ProQR Therapeutics had annual revenue of 19.55M with 196.41% growth.
Revenue (ttm) 
 17.14M EUR
Revenue Growth 
 +8.65%
P/S Ratio 
 13.23
Revenue / Employee 
 103,191 EUR
Employees 
 166
Market Cap 
286.54M USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth | 
|---|---|---|---|
| Dec 31, 2024 | 19.55M | 12.95M | 196.41% | 
| Dec 31, 2023 | 6.59M | 2.24M | 51.27% | 
| Dec 31, 2022 | 4.36M | 1.98M | 83.31% | 
| Dec 31, 2021 | 2.38M | 1.35M | 131.10% | 
| Dec 31, 2020 | 1.03M | -904.00K | -46.77% | 
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue | 
|---|---|
| UnitedHealth Group | 435.16B | 
| Johnson & Johnson | 92.15B | 
| Merck & Co. | 63.62B | 
| AbbVie | 58.33B | 
| AstraZeneca | 56.50B | 
| Novartis AG | 56.37B | 
| Eli Lilly and Company | 53.26B | 
| Novo Nordisk | 49.11B | 
PRQR News
- 10 days ago - ProQR Receives CTA Authorization for AX-0810 and Announces Virtual Investor and Analyst Event on November 3, 2025 - GlobeNewsWire
- 17 days ago - ProQR to Participate in Upcoming Investor Conferences in October 2025 - GlobeNewsWire
- 3 months ago - ProQR Announces Second Quarter 2025 Operating and Financial Results - GlobeNewsWire
- 3 months ago - ProQR Announces Upcoming Presentation at RNA Editing Summit - GlobeNewsWire
- 4 months ago - ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP - GlobeNewsWire
- 6 months ago - ProQR Announces Upcoming Scientific Presentations at ASGCT and TIDES Conferences - GlobeNewsWire
- 6 months ago - ProQR Announces First Quarter 2025 Operating and Financial Results - GlobeNewsWire
- 6 months ago - ProQR Announces Webcast of Presentation at the 2025 Citizens Life Sciences Conference - GlobeNewsWire